Aptevo Therapeutics Inc. (APVO): Nasdaq/NYSE listing notice — Aptevo Therapeutics receives Nasdaq bid price deficiency notice; delisting risk

Aptevo Therapeutics Inc.

Received Nasdaq letter on Sept 13, 2023; bid price below $1.00 for 30 consecutive days.
Must regain compliance by March 11, 2024; bid price must close at $1.00+ for 10 consecutive days.
If not compliant, may seek 180-day extension by meeting other listing standards and effecting reverse stock split.
Failure to regain compliance may result in delisting; company evaluating options to cure deficiency.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Aptevo Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

September 13, 2023, Aptevo Therapeutics Inc. (the “Company”) received a letter from the staff (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, or until March 11, 2024 (the “Compliance Date”), to regain compliance with

View on SEC.gov

Browse all listing & compliance notices →

Aptevo Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-048392

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.